A Two Part Seamless, Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of RO7034067 in Infants With Type 1 Spinal Muscular Atrophy
Phase of Trial: Phase II
Latest Information Update: 08 Jan 2018
At a glance
- Drugs RG 7916 (Primary)
- Indications Spinal muscular atrophy
- Focus Adverse reactions; Therapeutic Use
- Acronyms FIREFISH
- Sponsors Roche
- 08 Jan 2018 According to a PTC Therapeutics media release, this trial is anticipated to transition to the pivotal stage in the coming months.
- 18 Dec 2017 Planned End Date changed from 22 Jul 2020 to 1 Jan 2021.
- 18 Dec 2017 Planned primary completion date changed from 30 Apr 2019 to 30 Nov 2020.